Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.05%
#3 Meteora Meteora +11.55%
#4 Bitway Bitway +10.13%
#5 Glidr Glidr +9.59%
#6 Unit Pump Unit Pump +8.98%
#7 Pump.fun Pump.fun +8.98%
#8 OPENLOOT OPENLOOT +8.59%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.72%
#10 eCash eCash +7.02%
Coin of the day
PulseChain PulseChain
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Kedudukan dalam Saham #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Harga Saham
$0.55
Disegerakkan terakhir: 2025-02-11
Modal Pasaran
$28.90M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Marinus Pharmaceuticals, Inc. (MRNS)

Kategori

Healthcare
Nisbah P/B bagi Marinus Pharmaceuticals, Inc. (MRNS)
Nisbah P/B pada August 2026 TTM: 1.76
Menurut laporan kewangan dan harga saham terkini Marinus Pharmaceuticals, Inc., nisbah P/B semasa (TTM) ialah 1.76. Pada akhir 2022, nisbah P/B syarikat ialah 0.34.
Sejarah nisbah P/B untuk Marinus Pharmaceuticals, Inc. dari 2012 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
2026 (TTM) 1.76 -79.78%
2023 8.72 2,502.21%
2022 0.34 -83.55%
2021 2.04 236.14%
2020 0.61 80.74%
2019 0.34 -21.91%
2018 0.43 -48.12%
2017 0.83 261.21%
2016 0.23 -62.26%
2015 0.61 53.71%
2014 0.40 -76.83%
2013 1.71 -55.78%
2012 3.86 0.00%
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 259.68%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 110.34%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 253.98%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 42.09%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH